Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study.
Sabrina PaganoStephan J L BakkerCatherine JuillardStefania VossioDimitri MoreauKarim J BrandtFrançois MachRobin P F DullaartNicolas VuilleumierPublished in: Journal of translational medicine (2023)
AAA-1 induce a NAFLD-compatible phenotype in vitro and in mice. Intricate associations exist between AAA-1, CVD risk and FLI in the general population. Further work is required to refine the role of AAA-1 in NAFLD and to determine if the AAA-1 association with CVD is affected by hepatic steatosis.